A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

NCT07332117 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-01-12

No results posted yet for this study

Summary

To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Progressive Pulmonary Fibrosis

Interventions

OTHER

No Interventions

No intervention

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Royal Brompton & Harefield NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-09
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07332117 on ClinicalTrials.gov